The 11 signals we score every peptide vendor on
Our public rubric. Each signal, why it matters, how we score 0-3, and what each tier looks like in practice.
We write for mainstream adults figuring out peptides for the first time. No biohacker jargon. No protocol lists. Just the honest tradeoffs, the real risks, and the named sources.
Our public rubric. Each signal, why it matters, how we score 0-3, and what each tier looks like in practice.
The credentialed clinicians have covered GLP-1 drugs for years. Here is what they actually say, not the clickbait version.
Flight, accommodation, clinic selection, first visit, follow-up, and what to bring home. Written for first-timers.
The clinic route costs more and takes longer. The research-chem route puts more on you. Neither is wrong. Here is how to choose.
Heat degrades peptides. But not all peptides, not at all temperatures, not at all durations. The honest version of the cold-chain question.
The five things that matter on a COA, the three things that do not, and the one question that separates a serious vendor from a cargo-cult operator.
The phrase on every grey-market peptide site. What it actually means, what it does not mean, and why reading it wrong costs people money.
The tirzepatide weight-loss trial that reset the market. Here is what it tested, what it found, and the parts the press skipped.
What actually happens when you start tirzepatide. What is common, what is rare, what is serious, what to do about each.
What tirzepatide is, what it costs in Bangkok, how to tell a real clinic from a mediocre one, and the questions you should ask before your first injection.
Same drug class, different receptor profile. Here is the honest comparison, without the marketing gloss.
RFK and HHS moved most restricted peptides back to Category 1 in early 2026. Here is what that actually does, and what it does not.
Most peptide comparison sites are really just attack blogs. We do it differently, on purpose. Here is the logic.